Akinori Sato

J-GLOBAL         Last updated: Dec 3, 2019 at 20:32
 
Avatar
Name
Akinori Sato
Nickname
zenpaku
E-mail
zenpakundmc.ac.jp
Affiliation
National Defense Medical College
Section
Department of Urology
Job title
Lecturer
Research funding number
00296675
ORCID ID
0000-0001-9011-1756

Profile

Dr. Akinori Sato is the world’s leading researcher investigating the feasibility of using drug repositioning, endoplasmic reticulum stress, and histone acetylation to treat urological malignancies. His other important interests involve German, Germany, J. Brahms, and J.S. Bach. His German knowledge is facilitating good communication and on-going international research projects with German universities. He is also an expert on medical education. His educational activity has been highly regarded (he received a Best Teacher Award in 2018) and his students’ research projects have also received institutional and other awards.

Research Areas

 
 

Academic & Professional Experience

 
2015
 - 
Today
Lecturer, Department of Urology, National Defense Medical College
 
2006
 - 
2007
Visiting Researcher, Department of Urology, Heinrich Heine University, Düsseldorf, Germany
 
2006
   
 
Ph.D., Keio University
 
2004
 - 
2015
Research Associate, National Defense Medical College, Tokorozawa, Japan
 
1997
 - 
2001
Resident in Urology, Keio University and Its Affiliated Hospitals
 
1995
 - 
1997
Resident in Surgery, Keio University and Its Affiliated Hospitals
 
1995
   
 
M.D., Keio University, Tokyo, Japan
 

Education

 
1989
 - 
1995
School of Medicine, Keio University
 

Awards & Honors

 
Nov 2019
Excellence in Reviewing (Oncol Lett) - 2
 
Nov 2019
Medicine Innovates Key Scientific Article
 
https://medicineinnovates.com/metformin-panobinostat-combination-against-bladder-cancer-overcome-histone-deacetylase-inhibitor/
Nov 2019
Excellence in Reviewing (Oncol Lett) - 1
 
Oct 2019
Excellence in Reviewing (Int J Mol Med)
 
Sep 2019
Excellence in Reviewing (Mol Med Rep)
 
Sep 2019
Excellence in Reviewing (Exp Ther Med)
 
Sep 2019
The Top Peer Reviewer Award in Clinical Medicine, Publons
 
Sep 2019
The Top Peer Reviewer Award in Cross-Field, Publons
 
Aug 2019
Excellence in Reviewing (Mol Med Rep)
 
Aug 2019
Excellence in Reviewing (Int J Mol Med)
 
Jun 2019
Excellence in Reviewing (Mol Med Rep)
 
Jun 2019
Excellence in Reviewing (Exp Ther Med)
 
May 2019
xcellence in Reviewing (Exp Ther Med) - 2
 
May 2019
Excellence in Reviewing (Oncol Lett) - 2
 
May 2019
Excellence in Reviewing (Oncol Lett) - 1
 
May 2019
Excellence in Reviewing (Exp Ther Med) - 1
 
Apr 2019
Excellence in Reviewing (Exp Ther Med)
 
Apr 2019
Excellence in Reviewing (Oncol Lett)
 
Apr 2019
Excellence in Reviewing (Mol Med Rep)
 
Mar 2019
Excellence in Reviewing (Int J Mol Med)
 
Mar 2019
Excellence in Reviewing (Exp Ther Med) - 2
 
Mar 2019
Excellence in Reviewing (Oncol Rep)
 
Mar 2019
Excellence in Reviewing (Exp Ther Med) - 1
 
Feb 2019
Excellence in Reviewing (Exp Ther Med)
 
Feb 2019
Excellence in Reviewing (Oncol Rep)
 
Jan 2019
Excellence in Reviewing (Exp Ther Med)
 
Dec 2018
Excellence in Reviewing (Biomed Rep)
 
Nov 2018
Excellence in Reviewing (Oncol Lett) - 2
 
Nov 2018
Excellence in Reviewing (Oncol Lett) - 1
 
Oct 2018
Excellence in Reviewing (Mol Med Rep)
 
Oct 2018
Excellence in Reviewing (Oncol Lett)
 
Sep 2018
Excellence in Reviewing (Exp Ther Med)
 
Sep 2018
Publons Peer Review Awards 2018 "Top 1% in Field"
 
May 2018
Excellence in Reviewing (Exp Ther Med)
 
May 2018
Excellence in Reviewing (Int J Mol Med)
 
May 2018
Excellence in Reviewing (Int J Oncol)
 
May 2018
Best Teacher Award (National Defense Medical College)
 
Apr 2018
Excellence in Reviewing (Int J Oncol)
 
Mar 2018
Excellence in Reviewing (Exp Ther Med)
 
Feb 2018
Excellence in Reviewing (Exp Ther Med)
 
Feb 2018
Excellence in Reviewing (Oncol Lett)
 
Jan 2018
Excellence in Reviewing (Mol Med Rep)
 
Dec 2017
Excellence in Reviewing (Exp Ther Med)
 
Oct 2017
Excellence in Reviewing (Oncol Lett)
 
Oct 2017
Excellence in Reviewing (Mol Clin Oncol)
 
Sep 2017
Excellence in Reviewing (Exp Ther Med)
 
Aug 2017
Excellence in Reviewing (Exp Ther Med)
 
Jul 2017
URO TODAY "Beyond the Abstract"
Winner: Makoto Isono
 
Jul 2017
Excellence in Reviewing (Mol Clin Oncol)
 
May 2017
Excellence in Reviewing (Mol Med Rep)
 
Mar 2017
Best Poster Award at the 32nd EAU Congress
 
Dec 2016
Excellence in Reviewing (Oncol Lett)
 
Dec 2016
Excellence in Reviewing (Mol Med Rep)
 
Sep 2016
Excellence in Reviewing (Oncol Lett)
 
Feb 2016
Excellence in Reviewing (Exp Ther Med)
 
Apr 2014
The 102nd JUA Annual Meeting Award
 
Jul 2013
URO TODAY "Beyond the Abstract"
 
May 2013
Global Medical Discovery Key Scientific Article
 
Mar 2013
Best Poster Award at the 28th EAU Congress
 
Dec 2012
The Journal of Urology "This Month in Investigative Urology"
 
Mar 2011
Best Poster Award at the 26th EAU Congress
 
Apr 2011
The 99th JUA Annual Meeting Award
 
Oct 2011
Poster Award at the 76th Annual Meeting of the Eastern Section of the JUA
 
Nov 2010
NDMC Congress Award
 
Feb 2008
Tamura Award (Keio University)
 

Published Papers

 
Metformin augments panobinostat's anti-bladder cancer activity by activating AMP-activated protein kinase.
Okubo K, Isono M, Asano T, Sato A*.
Translational Oncology   12(4) 669-682   Apr 2019   [Refereed]
Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells.
Okubo K, Isono M, Miyai K, Asano T, Sato A*.
Cancer Science   doi: 10.1111/cas.14225. [Epub ahead of print]   Nov 2019   [Refereed]
Lopinavir-ritonavir combination induces endoplasmic reticulum stress and kills urological cancer cells.
Okubo K, Isono M, Asano T, Sato A*.
Anticancer Research   39(11) 5891-5901   Nov 2019   [Refereed]
Nelfinavir induces endoplasmic reticulum stress and sensitizes renal cancer cells to TRAIL.
Okubo K, Sato A*, Isono M, Asano T, Asano T.
Anticancer Research   38(8) 4505-4514   Aug 2018   [Refereed]
Panobinostat and nelfinavir inhibit renal cancer growth by inducing endoplasmic reticulum stress.
Okubo K, Isono M, Asano T, Sato A*.
Anticancer Research   38(10) 5615-5626   Oct 2018   [Refereed]
Evaluation of therapeutic potential of phenoxodiol, a novel isoflavone analog, in renal cancer cells.
Isono M, Sato A, Asano T, Okubo K, Asano T.
Anticancer Research   38(10) 5709-5716   Oct 2018   [Refereed]
Bosniak category III renal cysts caused by crizotinib in an anaplastic lymphoma kinase gene-rearranged non-small cell lung cancer patient.
Okubo K, Sato A*, Nakamoto K, Hatanaka Y, Isono M, Hatanaka M, Suyama Y, Shinmoto H, AsanoT.
Urology   121 e3-e4   Nov 2018   [Refereed]
A case of mucosa-associated lymphoid tissue lymphoma of the bladder successfully treated with radiotherapy.
Isono M, Sato A*, Kimura F, Asano T.
Urology Case Reports   16 1-3   Sep 2017   [Refereed]
Tachi K, Sato A*, Kouzaki Y, Maeda T, Kawana A, Asano T.
Urology Case Reports   14 24-26   Jun 2017   [Refereed]
Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
Isono M, Hoffmann MJ, Pinkerneil M, Sato A, Michaelis M, Cinatl J Jr, Niegisch G, Schulz WA.
Journal of Experimental & Clinical Cancer Research   36(1) doi: 10.1186/s13046-016-0473-1   Jan 2017   [Refereed]
Nelfinavir and ritonavir kill bladder cancer cells synergistically by inducing endoplasmic reticulum stress.
Sato A*, Asano T, Okubo K, Isono M, Asano T.
Oncology Research   26(2) 323-332   Mar 2018   [Refereed]
Sato A*, Asano T, Okubo K, Isono M, Asano T.
Cancer Science   108(6) 1194-1202   Jun 2017   [Refereed]
Kouzaki Y, Maeda T, Sasaki H, Tamura S, Hamamoto T, Yuki A, Sato A, Miyahira Y, Kawana A.
PLoS One   10(7) e0133759   Jul 2015   [Refereed]
Sato A*.
OncoTargets and Therapy   8 761-768   Apr 2015   [Refereed]
Ritonavir interacts with panobinostat to enhance histone acetylation and inhibit renal cancer growth synergistically
Sato A*, Asano T, Isono M, Ito K, Asano T
Molecular and Clinical Oncology   2(6) 1016-1022   Aug 2014   [Refereed]
Sato A*, Asano T, Ito K, Asano T
The Journal of Urology   188(6) 2410-2418   Dec 2012   [Refereed]
Sato A*, Asano T, Ito K, Asano T
International Journal of Oncology   41(1) 46-52   Mar 2012   [Refereed]
Sato A, Asano T, Ito K, Asano T
Urology   79(4) 966.e13-966.e21   Jan 2012   [Refereed]
Sato A*.
OncoTargets and Therapy   5 67-76   2012   [Refereed][Invited]
A novel treatment strategy against renal cancer by enhancing protein ubiquitination
Sato A*
J. Natl. Def. Med. Coll.   37(1) 1-7   2012   [Refereed][Invited]

Misc

 
Vorinostat and bortezomib, an innovative treatment strategy against advanced prostate cancer - ready for clinical trial, "Beyond the Abstract," by Masamichi Hayakawa, MD, PhD
Masamichi Hayakawa
UroToday      Jul 2013   [Invited]
685 DETECTION OF FACTORS AFFECTING EARLY BLADDER RECURRENCE AFTER NEPHROURETERECTOMY IN PATIENTS WITH N0M0 UPPER URINARY TRACT UROTHELIAL CARCINOMA
Kenji Kuroda, Junichi Asakuma, Akio Horiguchi, Shinsuke Tasaki, Akinori Sato, Kenji Seguchi, Keiichi Ito, Tomohiko Asano
The Journal of Urology   189(4) Supplement e281   Apr 2013
684 PREOPERATIVE RISK FACTORS FOR EXTRAVESICAL RECURRENCE IN PATIENTS WITH URETERAL CANCER WHO UNDERWENT RADICAL NEPHROURETERECTOMY
Keiichi Ito, Kenji Kuroda, Junichi Asakuma, Shinsuke Hamada, Kazuyoshi Tachi, Shinsuke Tasaki, Akinori Sato, Akio Horiguchi, Kenji Seguchi, Tomohiko Asano
The Journal of Urology   189(4) Supplement e281   Apr 2013
162 PANOBINOSTAT SYNERGIZES WITH BORTEZOMIB TO INDUCE ENDOPLASMIC RETICULUM STRESS AND UBIQUITINATED PROTEIN ACCUMULATION IN RENAL CANCER CELLS
Akinori Sato, Takako Asano, Keiichi Ito, Tomohiko Asano
The Journal of Urology   189(4) Supplement e67   Apr 2013
593 RITONAVIR COMBINED WITH BORTEZOMIB SYNERGISTICALLY INDUCES ENDOPLASMIC RETICULUM STRESS AND UBIQUITINATED PROTEIN ACCUMULATION IN BLADDER CANCER CELLS
Akinori Sato, Takako Asano, Keiichi Ito, Tomohiko Asano
The Journal of Urology   189(4) Supplement e242-e243   Apr 2013
Karl-Erik Andersson
The Journal of Urology   188 2033-2034   Dec 2012
295 DOCOSAHEXAENOIC ACID AS A NOVEL THERAPEUTIC AGENT FOR RENAL CELL CARCINOMA
Shinsuke Tasaki, Akiio Horiguchi, Takako Asano, Kenji Kuroda, Akinori Sato, Jyunichi Asakuma, Kenji Seguchi, Masamichi Hayakawa, Keiichi Ito, Tomohiko Asano
The Journal of Urology   187(4) Supplement e120   Apr 2012
2068 PREDICTION OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY USING A PERITUMORAL LYMPHATIC VESSEL DENSITY PARAMETER IN BIOPSY SPECIMENS FROM PATIENTS WITH LOCALIZED PROSTATE CANCER
Kenji Kuroda, Akio Horiguchi, Takako Asano, Shinsuke Tasaki, Akinori Sato, Junichi Asakuma, Keiichi Ito, Kenji Seguchi, Masamichi Hayakawa, Tomohiko Asano
The Journal of Urology   187(4) Supplement e834   Apr 2012
698 LOW LEVELS OF SERUM OMEGA-3 POLYUNSATURATED FATTY ACID ARE ASSOCIATED WITH TUMOR AGGRESSIVENESS AND POOR PROGNOSIS IN RENAL CELL CARCINOMA
Shinsuke Tasaki, Akio Horiguchi, Takako Asano, Kenji Kuroda, Akinori Sato, Jyunichi Asakuma, Kenji Seguchi, Masamichi Hayakawa, Keiichi Ito, Tomohiko Asano
The Journal of Urology   187(4) Supplement e286   Apr 2012
Akinori Sato, Takako Asano, Keiichi Ito, Tomohiko Asano
The Journal of Urology   187(4) Supplement e324   Apr 2012
234 COMBINATION THERAPY WITH SUBEROYLANILIDE HYDROXAMIC ACID AND BORTEZOMIB INDUCES HISTONE ACETYLATION AND PROTEIN UBIQUITINATION SYNERGISTICALLY IN RENAL CANCER CELLS
Akinori Sato, Takako Asano, Akio Horiguchi, Keiichi Ito, Makoto Sumitomo, Tomohiko Asano
The Journal of Urology   185(4) Supplement e95   Apr 2011
235 RITONAVIR AND BORTEZOMIB INHIBIT RENAL CANCER GROWTH BY INDUCING ENDOPLASMIC RETICULUM STRESS AND PROTEIN UBIQUITINATION
Akinori Sato, Takako Asano, Akio Horiguchi, Keiichi Ito, Makoto Sumitomo, Tomohiko Asano
The Journal of Urology   185(4) Supplement e95-e96   Apr 2011
739 RITONAVIR AND BORTEZOMIB INHIBIT RENAL CANCER GROWTH BY ENHANCING PROTEIN UBIQUITINATION SYNERGISTICALLY
A. Sato, T. Asano, A. Horiguchi, K. Ito, M. Sumitomo, T. Asano
European Urology Supplements   10(2) 235   Mar 2011
280 HIV protease inhibitor ritonavir increases heat sensitivity of renal cancer cells by inhibiting heat-induced NF-kappaB activation
A. Sato, T. Asano, J. Asakuma, A. Horiguchi, K. Ito, M. Sumitomo, T. Asano
EJC Supplements   8(5) 73   Jun 2010
228 Renal cancer histone acetylation and protein ubiquitination enhanced synergistically by bortezomib and suberoylanilide hydroxamic acid
A. Sato, T. Asano, A. Horiguchi, K. Ito, M. Sumitomo, T. Asano
EJC Supplements   8(5) 60   Jun 2010
84 COMBINATION THERAPY WITH 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN AND RITONAVIR INHIBITS EXPRESSION OF HEAT SHOCK FACTOR 1 IN RENAL CANCER CELLS
Akinori Sato, Takako Asano, Junichi Asakuma, Keiichi Ito, Akio Horiguchi, Makoto Sumitomo, Tomohiko Asano
The Journal of Urology   183(4) Supplement e35   Apr 2010
A NOVEL COMBINATION THERAPY USING SUBEROYLANILIDE HYDROXAMIC ACID AND RITONAVIR TO TREAT PROSTATE CANCER
Akinori Sato, Takako Asano, Akio Horiguchi, Keiichi Ito, Makoto Sumitomo, Tomohiko Asano
The Journal of Urology   181(4) Supplement 52   Apr 2009
COMBINED EFFECTS OF SUBEROYLANILIDE HYDROXAMIC ACID AND RITONAVIR IN RENAL CANCER CELLS
Akinori Sato, Takako Asano, Akio Horiguchi, Keiichi Ito, Makoto Sumitomo, Tomohiko Asano
The Journal of Urology   181(4) Supplement 158   Apr 2009
382 HEAT SHOCK PROTEIN 27 OVER EXPRESSION IS AN INDICATOR OF TUMOR AGGRESSIVENESS AND POOR PROGNOSIS IN RENAL CELL CARCINOMA
Junichi Asakuma, Makoto Sumitomo, Akio Horiguchi, Takako Asano, Hidehiko Yoshii, Shinsuke Tasaki, Kenji Kuroda, Akinori Sato, Keiichi Ito, Kenji Seguchi, Masamichi Hayakawa, Tomohiko Asano
The Journal of Urology   185(4) Supplement e154-e155   Apr 2011
965 IMPACT OF INCREASED EXPRESSION OF GLUCOSE-REGULATED PROTEIN 78 ON CLINICOPATHOLOGICAL PARAMETERS AND PROGNOSIS IN RENAL CELL CARCINOMA
Kenji Kuroda, Akio Horiguchi, Takako Asano, Shinsuke Tasaki, Junichi Asakuma, Hidehiko Yoshii, Akinori Sato, Keiichi Ito, Kenji Seguchi, Makoto Sumitomo, Tomohiko Asano
The Journal of Urology   185(4) Supplement e389   Apr 2011
1850 PERITUMORAL LYMPHATIC VESSEL DENSITY IN PROSTATE BIOPSY CORES AS PREDICTOR OF LYMPHATIC INVASION IN SURGICAL SPECIMENS FROM RADICAL PROSTATECTOMY
Kenji Kuroda, Akio Horiguchi, Takako Asano, Makoto Sumitomo, Keiichi Ito, Junichi Asakuma, Akinori Sato, Masamichi Hayakawa, Tomohiko Asano
The Journal of Urology   183(4) Supplement e718   Apr 2010
832 IMPACT OF POSTOPERATIVE C-REACTIVE PROTEIN LEVEL ON RECURRENCE AND PROGNOSIS IN PATIENTS WITH N0M0 RENAL CELL CARCINOMA (RCC)
Keiichi Ito, Hidehiko Yoshii, Kenji Kuroda, Akinori Sato, Junichi Asakuma, Akio Horiguchi, Makoto Sumitomo, Tomohiko Asano
The Journal of Urology   183(4) Supplement e325   Apr 2010
69 PHARMACOLOGICAL INHIBITOR OF FATTY ACID SYNTHASE SUPPRESSES GROWTH AND INVASIVENESS OF RENAL CANCER CELLS
Akio Horiguchi, Takako Asano, Akinori Sato, Junichi Asakuma, Keiichi Ito, Makoto Sumitomo, Masamichi Hayakawa, Tomohiko Asano
The Journal of Urology   183(4) Supplement e29-e30   Apr 2010
OBESITY AS A STRONG PREDICTOR OF BIOCHEMICAL RECURRENCE AFTER HIGH-INTENSITY FOCUSED ULTRASOUND FOR PROSTATE CANCER
Makoto Sumitomo, Junichi Asakuma, Hidehiko Yoshii, Akio Horiguchi, Akinori Sato, Keiichi Ito, Masamichi Hayakawa, Tomohiko Asano
The Journal of Urology   181(4) Supplement 50-51   Apr 2009
229 INHIBITION OF THE GROWTH AND TUMOR ANGIOGENESIS OF RENAL CELL CARCINOMA BY THE STAT3 INHIBITOR WP1066
Akio Horiguchi, Takako Asano, Kenji Kuroda, Akinori Sato, Junichi Asakuma, Keiichi Ito, Masamichi Hayakawa, Makoto Sumitomo, Tomohiko Asano
The Journal of Urology   183(4) Supplement e93
167 RITONAVIR INTERACTS WITH PANOBINOSTAT TO ENHANCE HISTONE ACETYLATION AND INHIBIT RENAL CANCER GROWTH SYNERGISTICALLY
Akinori Sato, Takako Asano, Keiichi Ito, Tomohiko Asano
The Journal of Urology   189(4) Supplenment e69   Apr 2013

Conference Activities & Talks

 
Basic research program at the department of Urology, National Defense Medical College
Sato A.
The 51st Annual Meeting of the Japan Society for Medical Education   Jul 2019   
Die verschwundene Proteine: where are they? [Invited]
Sato A.
12th Triennial Meeting German-Japanese Confederation of Urology   Jun 2019   
Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells by activating AMP activated protein kinase
Okubo K, Isono M, Asano T, Sato A.
The 114th American Urological Association Annual Meeting   May 2019   
Cobicistat, a potent CYP3A4 inhibitor, acts synergistically with oprozomib to cause endoplasmic reticulum stress in bladder cancer cells
Sato A, Asano T, Isono M, Okubo K.
The 114th American Urological Association Annual Meeting   May 2019   
Panobinostat and ritonavir cause bladder cancer apoptosis by inducing endoplasmic reticulumstress and histone acetylation synergistically
Sato A, Asano T, Isono M, Okubo K.
The 114th American Urological Association Annual Meeting   May 2019   
Cobicistat, a potent inhibitor of CYP3A, enhances the antineoplastic activity of ixazomib in renal cancer cells
Asano T, Sato A, Isono M, Okubo K.
The 114th American Urological Association Annual Meeting   May 2019   
The ataxia telangiectasia and Rad3-related kinase inhibitor AZD6738  overcomes cisplatin resistance in cisplatin-resistant bladder cancer cells
Isono M, Okubo K, Asano T, Sato A.
The 34th European Association of Urology Congress   Mar 2019   
Cobicistat, a potent CYP3A4 inhibitor, acts synergistically with oprozomib to cause endoplasmic reticulum stress in bladder cancer cells
Sato A, Asano T, Isono M, Okubo K.
The 34th European Association of Urology Congress   Mar 2019   
Ritonavir and ixazomib inhibit renal cancer growth in vitro and in vivo by inducing endoplasmic reticulum stress synergistically
Ritonavir and ixazomib inhibit renal cancer growth in vitro and in vivo by inducing endoplasmic reticulum stress synergistically
The 113th American Urological Association Annual Meeting   May 2018   
Metformin augments panobinostat’s antineoplastic activity in bladder cancer cells by activating AMP-activated protein kinase
Okubo K, Sato A, Asano T, Isono M, Asano T.
The 33rd European Association of Urology Congress   Mar 2018   
The ataxia telangiectasia and Rad3-related kinase inhibitor AZD6738 sensitizes bladder cancer cells to gemcitabine
Isono M, Sato A, Okubo K, Asano T, Asano T.
The 33rd European Association of Urology Congress   Mar 2018   
Ritonavir and oprozomib cause bladder cancer apoptosis synergistically by inducing endoplasmic reticulum stress
Sato A, Asano T, Okubo K, Isono M, Asano T.
The 33rd European Association of Urology Congress   Mar 2018   
(EAU chair)Poster Session 79: Urothelial tumours: Molecular subtypes and clinical relevance [Invited]
Sato A.
The 33rd European Association of Urology Congress   Mar 2018   
Ritonavir, a potent inhibitor of CYP3A4, enhances the anticancer effects of entinostat in renal cancer cells in vitro and in vivo
Akinori SatoAsano T, Sato A, Okubo K, Isono M, Asano T.
The 112th American Urological Association Annual Meeting   May 2017   
Lopinavir synergizes with ritonavir to induce bladder cancer apoptosis by causing histone acetylation and endoplasmic reticulum stress
Asano T,
The 32nd European Association of Urology Congress   Mar 2017   
(EAU Session chair) Poster Session 73: Immune therapy and targeted therapy in urothelial cancer [Invited]
Sato A.
The 32nd European Association of Urology Congress   Mar 2017   
Panobinostat and ixazomib inhibit bladder cancer growth synergistically by increasing histone acetylation and inducing endoplasmic reticulum stress(Best Poster受賞)
Sato A, Isono M, Asano T, Okubo K, Asano T.
The 32nd European Association of Urology Congress   Mar 2017   
Ritonavir, a potent inhibitor of P-glycoprotein, enhances the anticancer effects of romidepsin in renal cancer cells
Sato A, Asano T, Okubo K, Isono M, Asano T.
The 32nd European Association of Urology Congress   Mar 2017   
The novel checkpoint kinase 1 inhibitor MK-8776 strongly sensitizes bladder cancer cells to gemcitabine
Isono M, Sato A, Okubo K, Asano T, Hoffmann MJ, Schulz WA, Asano T.
The 32nd European Association of Urology Congress   Mar 2017   
Panobinostat interacts with nelfinavir to inhibit renal cancer growth by causing endoplasmic reticulum stress
Okubo K , Sato A, Asano T, Isono M, Asano T.
The 31nd European Association of Urology Congress   Mar 2017   
Ritonavir interacts with ixazomib synergistically to cause ubiquitinated protein accumulation and endoplasmic reticulum stress in bladder cancer cells
Sato A, Asano T, Isono M, Okubo K, Asano T.
24th Biennial Congress of the European Association for Cancer Research   Jul 2016   
ER stress: A novel approach to treating urological malignancies [Invited]
Sato A
11th Triennial Meeting German-Japanese Confederation of Urology   Jun 2016   
Nelfinavir induces endoplasmic reticulum stress and sensitizes renal cancer cells to tumor necrosis factor-related apoptosis-inducing ligand
Okubo K, Sato A, Asano T, Isono M, Asano T.
The 111th American Urological Association Annual Meeting   May 2016   
Ritonavir synergizes with delanzomib to cause endoplasmic reticulum stress in renal cancer cells
Isono M, Sato A, Okubo K, Asano T, Asano T.
The 111th American Urological Association Annual Meeting   May 2016   
Ritonavir and delanzomib inhibit renal cancer growth in vitro and in vivo by inducing endoplasmic reticulum stress synergistically
Isono M, Sato A, Asano T, Okubo K, Schulz WA, Asano T.
The 31st European Association of Urology Congress   Mar 2016   
Combination of human immunodeficiency virus protease inhibitors causes bladder cancer apoptosis synergistically by inducing endoplasmic reticulum stress and histone acetylation
Sato A, Asano T, Isono M, Okubo K, Asano T.
The 31st European Association of Urology Congress   Mar 2016   
Ritonavir synergizes with delanzomib to cause endoplasmic reticulum stress and autophagy in renal cancer cells
Isono M, Sato A, Asano T, Okubo K, Schulz WA, Asano T.
The 67th German Urological Association Annual Meeting   Sep 2015   
Clinical perspective in genitourinary malignancies [Invited]
Sato A
IAEA/RCA Regional Training Course   Jul 2015   
Ritonavir synergizes with carfilzomib to cause endoplasmic reticulum stress and autophagy in bladder cancer cells
Sato A, Isono M, Asano T, Okubo K, Asano T.
The 30th European Association of Urology Congress   Mar 2015   
Is estimated glomerular filtration rate a significant predictor of prostate cancer?
Isono M, Sato A, Tsujita Y, Kuroda K, Asakuma J, Horiguchi A, Seguchi K, Ito K, Asano T
The 34th Congress of the Societe Internationale d'Urologie   Oct 2014   
ER stress: A novel approach to treating urological malignancies [Invited]
Sato A
Urologische Klinik CE Meeting (Heinrich Heine University)   Jul 2014   
Ubiquitinated protein accumulation: A novel approach to treating bladder cancer
Sato A, Asano T, Isono M, Ito K, Asano T
The 23rd Biennial Congress of the European Association for Cancer Research   Jul 2014   
Ritonavir interacts with belinostat to cause endoplasmic reticulum stress and histone acetylation synergistically in renal cancer cells
Isono M, Sato A, Asano T, Ito K, Asano T
The 23rd Biennial Congress of the European Association for Cancer Research   Jul 2014   
Romidepsin combined with ritonavir exhibits strong cytotoxicity in renal cancer cells by synergistically inducing histone acetylation and endoplasmic reticulum stress
Sato A, Asano T, Isono M, Ito K, Asano T
The 109th American Urological Association Annual Meeting   May 2014   
Ritonavir synergizes with carfilzomib to induce endoplasmic reticulum stress and autophagy in renal cancer cells
Sato A, Asano T, Isono M, Ito K, Asano T
The 109th American Urological Association Annual Meeting   May 2014   
Bortezomib interacts synergistically with belinostat to cause ubiquitinated protein accumulation in renal cancer cells
Asano T, Sato A, Isono M, Ito K, Asano T
The 109th American Urological Association Annual Meeting   May 2014   
Ritonavir combined with bortezomib synergistically induces endoplasmic reticulum stress and ubiquitinated protein accumulation in bladder cancer cells
Sato A, Asano T, Ito K, Asano T
The 108th American Urological Association Annual Meeting   May 2013   
Ritonavir interacts with panobinostat to enhance histone acetylation and inhibit renal cancer growth synergistically
Sato A, Asano T, Ito K, Asano T
The 108th American Urological Association Annual Meeting   May 2013   
Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells
Sato A, Asano T, Ito K, Asano T
The 108th American Urological Association Annual Meeting   May 2013   
Ritonavir and bortezomib inhibit bladder cancer growth by inducing endoplasmic reticulum stress and ubiquitinated protein accumulation synergistically(Best Poster Award)
Sato A, Asano T, Ito K, Asano T
The 28th European Association of Urology Congress   Mar 2013   
Bortezomib synergizes with vorinostat to cause ubiquitinated protein accumulation and histone acetylation in bladder cancer cells
Sato A, Asano T, Ito K, Asano T
The 28th European Association of Urology Congress   Mar 2013   
Ritonavir, a potent inhibitor of CYP3A4, enhances the anticancer effects of panobinostat in renal cancer cells in vitro and in vivo
Sato A, Asano T, Ito K, Asano T
The 28th European Association of Urology Congress   Mar 2013   
Panobinostat and bortezomib inhibit renal cancer growth in vitro and in vivo by inducing endoplasmic reticulum stress and ubiquitinated protein accumulation synergistically
Sato A, Asano T, Ito K, Asano T
The 28th European Association of Urology Congress   Mar 2013   
Ritonavir interacts with bortezomib synergistically to enhance endoplasmic reticulum stress in prostate cancer cells.
Sato A, Asano T, Ito K, Asano T
The 107th American Urological Association Annual Meeting   May 2012   
What wandering along the Rhein brought me: The idea of treating urological malignancies by causing the accumulation of ubiquitinated proteins [Invited]
Sato A
The 100th Japanese Urological Association Annual Meeting   Apr 2012   
Vorinostat interacts with bortezomib to enhance protein ubiquitination synergistically in prostate cancer cells
Sato A, Asano T, Ito K, Asano T
The 27th European Association of Urology Congress   Feb 2012   
Combination therapy with suberoylanilide hydroxamic acid and bortezomib induces histone acetylation and protein ubiquitination synergistically in renal cancer cells
Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M, Asano T
The 106th American Urological Association Annual Meeting   May 2011   
Ritonavir and bortezomib inhibit renal cancer growth by inducing endoplasmic reticulum stress and protein ubiquitination
Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M, Asano T
The 106th American Urological Association Annual Meeting   May 2011   
Ritonavir and bortezomib inhibit renal cancer growth by enhancing protein ubiquitination synergistically (Best Poster Presentation Award)
Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M, Asano T
The 26th European Association of Urology Congress   Mar 2011   
HIV protease inhibitor ritonavir increases heat sensitivity of renal cancer cells by inhibiting heat-induced NF-kappaB activation
Sato A, Asano T, Asakuma J, Horiguchi A, Ito K, Sumitomo M, Asano T
The 21st Meeting of the European Association for Cancer Research   Jun 2010   

Research Grants & Projects

 
Ministry of Education, Culture, Sports, Science and Technology: Grants-in-Aid for Scientific Research(基盤研究(C))
Project Year: 2000 - 2001    Investigator(s): 朝倉博孝, Fumio NAKAJIMA
It is known that oxalate and calcium oxalate monohydrate (COM) crystals induce urothelium injury. Although xanthine oxidase inhibitor (allopurinol, oxypurinol) can protect the cell injury which is induced by oxalate and calcium crystals, whether x...